BEIJING, Aug. 31, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases, achieved key milestones in its product portfolio and just announced its interim results for 2025H1.
Business Highlights: Big Movement in Commercialization, Registration and Clinical
LuX-Valve Series, TTVR system
- In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration application has received acceptance from NMPA, entering registration stage.
- In Europe, LuX-Valve Plus has completed 6-month follow-up of TRINITY study, its clinical trial for CE Marking and is currently under registration review.
- In U.S., the IDE Early Feasibility Study (EFS) of LuX-Valve Plus has …